Zobrazeno 1 - 6 of 6 pro vyhledávání: '"Elisabeta Gherga"'
1
Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial
Autor: Yungan TAO, Xu-Shan Sun, Yoann Pointreau, Christophe Le Tourneau, Christian Sire, Marie-Christine Kaminsky, Alexandre Coutte, Marc Alfonsi, Benôit Calderon, Pierre Boisselier, Laurent Martin, Jessica Miroir, Jean-Francois Ramee, Jean-Pierre Delord, Florian Clatot, Frederic Rolland, Julie Villa, Nicolas Magne, Olgun Elicin, Elisabeta Gherga, France Nguyen, Cédrik Lafond, Guillaume Bera, Valentin Calugaru, Lionnel Geoffrois, Bruno Chauffert, Lars Damstrup, Philippa Crompton, Abdallah Ennaji, Kathrin Gollmer, Heidi Nauwelaerts, Jean Bourhis
Publikováno v: European Journal of Cancer
European Journal of Cancer, 2023, 183, pp.24-37. ⟨10.1016/j.ejca.2022.12.015⟩
Tao, Yungan; Sun, Xu-Shan; Pointreau, Yoann; Le Tourneau, Christophe; Sire, Christian; Kaminsky, Marie-Christine; Coutte, Alexandre; Alfonsi, Marc; Calderon, Benôit; Boisselier, Pierre; Martin, Laurent; Miroir, Jessica; Ramee, Jean-Francois; Delord, Jean-Pierre; Clatot, Florian; Rolland, Frederic; Villa, Julie; Magne, Nicolas; Elicin, Olgun; Gherga, Elisabeta; ... (2023). Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial. European journal of cancer, 183, pp. 24-37. Elsevier 10.1016/j.ejca.2022.12.015
International audience; Introduction: We report long-term efficacy and overall survival (OS) results from a randomised, double-blind, phase 2 study (NCT02022098) investigating xevinapant plus standard-of-care chemoradiotherapy (CRT) vs. placebo plus
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::211a0df94cec42ecc06dd2e0c99d51be
Zobrazit plný text záznamu
5
Approach to oligometastatic disease in head and neck cancer, on behalf of the GORTEC
Autor: Adeline Péchery, Jean Bourhis, Elisabeta Gherga, Cécile Michel, Juliette Thariat, Xu Shan Sun, Dominique De Raucourt, Bernard Gery, C. Florescu, Emmanuel Babin
Publikováno v: Future Oncology. 14:877-889
Median survival for recurrent/metastatic head and neck squamous cell cancer (HNSCC) patients is about 10 months after first-line best systemic treatment. We aimed to assess current approaches of oligometastatic HNSCC patients by the analysis of curre
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ba94531b4932443c95f5f60bf1ec97f
https://doi.org/10.2217/fon-2017-0468
Zobrazit plný text záznamu
6
FOLFOXIRI
Autor: Angélique, Vienot, Hortense, Chevalier, Clément, Bolognini, Elisabeta, Gherga, Elodie, Klajer, Aurélia, Meurisse, Marine, Jary, Stefano, Kim, Christelle, d'Engremont, Thierry, Nguyen, Fabien, Calcagno, Hamadi, Almotlak, Francine, Fein, Meher, Nasri, Syrine, Abdeljaoued, Anthony, Turpin, Christophe, Borg, Dewi, Vernerey
Publikováno v: World Journal of Gastrointestinal Oncology
BACKGROUND FOLFIRINOX regimen is the first-line reference chemotherapy (L1) in advanced pancreatic ductal adenocarcinoma (aPDAC). FOLFOXIRI, a schedule with a lower dose of irinotecan and no bolus 5-fluorouracil, has demonstrated efficacy and feasibi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::49486c447cc88a28bc34a4a5c8593e0b
https://pubmed.ncbi.nlm.nih.gov/32206183
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje